{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T05:09:19Z","timestamp":1778303359667,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.cpcardiol.2025.103057","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T16:07:31Z","timestamp":1744733251000},"page":"103057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["RNA-targeting therapies for amyloid transthyretin cardiomyopathy: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5918-3873","authenticated-orcid":false,"given":"Jo\u00e3o Victor de Oliveira","family":"Ramos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Vitor Andrade","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan Gadelha de Abrantes","family":"Formiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabyan Esberard de Lima","family":"Beltr\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo Dantas Tavares","family":"de Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e1bio","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.cpcardiol.2025.103057_bib0001","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid Cardiomyopathy: JACC State-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103057_bib0002","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40256-020-00461-7","article-title":"Tafamidis: a review in transthyretin amyloid cardiomyopathy","volume":"21","author":"Lamb","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.cpcardiol.2025.103057_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.751293","article-title":"Cardiac amyloidosis: a review of current imaging techniques","volume":"8","author":"Razvi","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2025.103057_bib0004","first-page":"59","volume":"18","author":"Brito","year":"2023"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103057_bib0005","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/joim.12383","article-title":"Cardiac amyloidosis: where are we today?","volume":"278","author":"Patel","year":"2015","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103057_bib0006","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment","volume":"28","author":"Siddiqi","year":"2018","journal-title":"Trends Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103057_bib0007","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13506129.2016.1160882","article-title":"Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis","volume":"23","author":"Butler","year":"2016","journal-title":"Amyloid"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103057_bib0008","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40259-023-00577-7","article-title":"RNA targeting and gene editing strategies for transthyretin amyloidosis","volume":"37","author":"Ioannou","year":"2023","journal-title":"BioDrugs"},{"issue":"9","key":"10.1016\/j.cpcardiol.2025.103057_bib0009","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1097\/MS9.0000000000001118","article-title":"The promise of RNA-based therapeutics in revolutionizing heart failure management - a narrative review of current evidence","volume":"85","author":"Aderinto","year":"2023","journal-title":"Ann Med Surg (Lond)"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103057_bib0010","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3390\/ijms25010328","article-title":"Molecular therapies in cardiovascular diseases: small interfering RNA in atherosclerosis, heart failure, and hypertension","volume":"25","author":"Sarzani","year":"2023","journal-title":"Int J Mol Sci."},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103057_bib0011","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1007\/s13311-021-01154-y","article-title":"Current and emerging therapies for hereditary transthyretin amyloidosis: strides towards a brighter future","volume":"18","author":"Obici","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103057_bib0012","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ajpath.2019.01.011","article-title":"Macrophage-mediated phagocytosis and dissolution of amyloid-like fibrils in mice, monitored by optical imaging","volume":"189","author":"Richey","year":"2019","journal-title":"Am J Pathol"},{"issue":"8","key":"10.1016\/j.cpcardiol.2025.103057_bib0013","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3390\/biomedicines10081906","article-title":"The journey of Human transthyretin: synthesis, structure stability, and catabolism","volume":"10","author":"Sanguinetti","year":"2022","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.cpcardiol.2025.103057_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163944","article-title":"Involvement of macrophages in the pathogenesis of familial amyloid polyneuropathy and efficacy of Human iPS cell-derived macrophages in its treatment","volume":"11","author":"Suenaga","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.cpcardiol.2025.103057_bib0015","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2025.103057_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1154594","article-title":"Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials","volume":"10","author":"Tomasoni","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"10.1016\/j.cpcardiol.2025.103057_bib0017","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.3390\/jcm11082148","article-title":"Treatment of transthyretin amyloid cardiomyopathy: the current options, the future, and the challenges","volume":"11","author":"Tsch\u00f6pe","year":"2022","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103057_bib0018","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1093\/pubmed\/fdac036","article-title":"Strengthening systematic reviews in public health: guidance in the Cochrane Handbook for Systematic Reviews of Interventions, 2nd edition","volume":"44","author":"Cumpston","year":"2022","journal-title":"J Public Health (Oxf)"},{"key":"10.1016\/j.cpcardiol.2025.103057_bib0019","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cpcardiol.2025.103057_bib0020","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103057_bib0021","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"HELIOS-B trial investigators and collaborators. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103057_bib0022","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 multicenter study of Revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"issue":"17","key":"10.1016\/j.cpcardiol.2025.103057_bib0023","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"APOLLO-B trial investigators. Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103057_bib0024","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40120-018-0106-z","article-title":"Characterizing the high disease burden of transthyretin amyloidosis for patients and caregivers","volume":"7","author":"Stewart","year":"2018","journal-title":"Neurol Ther"},{"key":"10.1016\/j.cpcardiol.2025.103057_bib0025","doi-asserted-by":"crossref","unstructured":"Ponti L., Hsu K., Damy T., et al. Burden of untreated transthyretin amyloid cardiomyopathy on patients and their caregivers by disease severity: results from a multicenter, non-interventional, real-world study. Front Cardiovasc Med. 2023 Aug 29;10:1238843. doi: 10.3389\/fcvm.2023.1238843. PMID: 37711563; PMCID: PMC10497948.","DOI":"10.3389\/fcvm.2023.1238843"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103057_bib0026","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/phar.4639","article-title":"Disease-modifying therapies for amyloid transthyretin cardiomyopathy: current and emerging medications","volume":"45","author":"Hellenbart","year":"2025","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103057_bib0027","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3390\/biomedicines11051275","article-title":"RNA Therapeutics: a healthcare paradigm shift","volume":"11","author":"Niazi","year":"2023","journal-title":"Biomedicines"},{"issue":"19","key":"10.1016\/j.cpcardiol.2025.103057_bib0028","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood.2023019884","article-title":"Hereditary transthyretin amyloidosis in the era of RNA interference, antisense oligonucleotide, and CRISPR-Cas9 treatments","volume":"142","author":"Adams","year":"2023","journal-title":"Blood"},{"issue":"2\u20133","key":"10.1016\/j.cpcardiol.2025.103057_bib0029","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2007.03.005","article-title":"RNAi therapeutics: principles, prospects and challenges","volume":"59","author":"Aagaard","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103057_bib0030","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00392-020-01799-3","article-title":"Diagnosis and treatment of cardiac amyloidosis: position statement of the German cardiac society (DGK)","volume":"110","author":"Yilmaz","year":"2021","journal-title":"Clin Res Cardiol"},{"issue":"16","key":"10.1016\/j.cpcardiol.2025.103057_bib0031","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103057_bib0032","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"16","author":"Maurer","year":"2023","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2025.103057_bib0033","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejim.2024.01.001","article-title":"Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy","volume":"123","author":"Porcari","year":"2024","journal-title":"Eur J Intern Med"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280625000799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280625000799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T04:13:12Z","timestamp":1778299992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280625000799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0146280625000799"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103057","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA-targeting therapies for amyloid transthyretin cardiomyopathy: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103057"}}